From Health Canada product monographs; label wording only, not a treatment recommendation.
Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ.
Covered without a code on the Ontario formulary: INSULIN LISPRO & INSULIN LISPRO PROTAMINE, INSULIN (30% NEUTRAL & 70% ISOPHANE) HUMAN BIOSYNTHETIC, INSULIN (ISOPHANE) HUMAN BIOSYNTHETIC, INSULIN ASPART 30% & INSULIN ASPART PROTAMINE 70%, INSULIN HUMAN BIOSYNTHETIC
INSULIN LISPRO & INSULIN LISPRO PROTAMINE · General benefit
INDICATIONS AND CLINICAL USE
HUMALOG (insulin lispro injection), HUMALOG MIX25 (25% insulin lispro injection, 75%
insulin lispro protamine suspension), and HUMALOG MIX50 (50% insulin lispro injection,
50% insulin lispro protamine suspension) are indicated for the treatment of patients with diabetes
mellitus who require insulin for the maintenance of normal glucose homeostasis.
PM: https://pdf.hres.ca/dpd_pm/00063278.PDF; date April 12, 2021; DIN 02240294; fetched 2026-09-10
Product monograph
HUMALOG
insulins are also indicated for the initial stabilization of diabetes mellitus.
PM: https://pdf.hres.ca/dpd_pm/00063278.PDF; date April 12, 2021; DIN 02240294; fetched 2026-09-10
Product monograph
HUMALOG 200 units/mL KwikPen (insulin lispro injection) is reserved for the treatment of
patients with diabetes requiring daily doses of more than 20 units of fast-acting insulin.
PM: https://pdf.hres.ca/dpd_pm/00063278.PDF; date April 12, 2021; DIN 02240294; fetched 2026-09-10
Product monograph
INSULIN (30% NEUTRAL & 70% ISOPHANE) HUMAN BIOSYNTHETIC · General benefit
1 INDICATIONS
Novolin®ge (Insulin, Human Biosynthetic) is indicated for:
• The treatment of patients with diabetes mellitus who require insulin for the control of
hyperglycemia.
PM: https://pdf.hres.ca/dpd_pm/00077108.PDF; date JAN 07, 2011; DIN 02024217; fetched 2026-09-10
Product monograph
INSULIN (ISOPHANE) HUMAN BIOSYNTHETIC · General benefit
1 INDICATIONS
Novolin®ge (Insulin, Human Biosynthetic) is indicated for:
• The treatment of patients with diabetes mellitus who require insulin for the control of
hyperglycemia.
PM: https://pdf.hres.ca/dpd_pm/00077108.PDF; date JAN 07, 2011; DIN 02024225; fetched 2026-09-10
Product monograph
INSULIN ASPART · Limited Use, codes 646 (1), General benefit (4)
1 Indications
NOVORAPID® (insulin aspart) is indicated for:
• The treatment of patients with diabetes mellitus who require insulin for the control of
hyperglycemia.
PM: https://pdf.hres.ca/dpd_pm/00084670.PDF; date 2026-05-12; DIN 02245397; fetched 2026-09-10
Product monograph
• The treatment of patients with diabetes mellitus who require insulin for the control of
hyperglycemia.
NOVORAPID® should normally be used in regimens together with an intermediate or long-acting insulin.
NOVORAPID® (10 mL vials) may also be used for continuous subcutaneous insulin infusion (CSII) in pump
systems which are licensed in Canada for insulin infusion.
PM: https://pdf.hres.ca/dpd_pm/00084670.PDF; date 2026-05-12; DIN 02245397; fetched 2026-09-10
Product monograph
INSULIN ASPART 30% & INSULIN ASPART PROTAMINE 70% · General benefit
The treatment of adult patients with diabetes mellitus who require insulin for the control
of hyperglycemia.
PM: https://pdf.hres.ca/dpd_pm/00062479.PDF; date JUL 11, 2017; DIN 02265435; fetched 2026-09-10
Product monograph
INSULIN HUMAN BIOSYNTHETIC · General benefit
1 INDICATIONS
Novolin®ge (Insulin, Human Biosynthetic) is indicated for:
• The treatment of patients with diabetes mellitus who require insulin for the control of
hyperglycemia.
PM: https://pdf.hres.ca/dpd_pm/00077108.PDF; date JAN 07, 2011; DIN 02024233; fetched 2026-09-10
Product monograph
Coverage source: ON formulary extract 2026-08-26